Lennon David James 4

4 · Whitehawk Therapeutics, Inc. · Filed Apr 3, 2026

AI-generated summary of this filing

Updated Apr 3, 2026

Whitehawk (WHWK) CEO Lennon David James Receives RSUs, Sells 26,858

What Happened

Lennon David James, CEO of Whitehawk Therapeutics (WHWK), had derivative awards settle/convert and received an award of 831,148 restricted stock units (RSUs) effective April 1, 2026. The filing shows conversion/exercise activity of 775,828 derivative units on April 1, 2026 (no cash proceeds shown).
A broker-assisted sale of 26,858 shares occurred on April 2, 2026 at $3.48 per share, generating $93,466. This sale was used to satisfy tax withholding associated with the RSU vesting.

Key Details

Transaction dates and prices:
- 2026-04-01: Grant/award of 831,148 RSUs at $0.00 (acquired).
- 2026-04-01: Conversion/exercise of 775,828 derivative units (reported with $0 proceeds).
- 2026-04-02: Open-market/broker-assisted sale of 26,858 shares at $3.48 = $93,466 (disposed).
Shares owned after the transaction: Not specified in the filing excerpt provided.
Footnotes of note:
- F1: Each RSU equals a contingent right to one share of common stock.
- F2: The April 2 sale was a broker-assisted sale to satisfy tax withholding on vested RSUs.
- F3: The RSUs are scheduled to vest 100% on the one‑year anniversary of the Vesting Commencement Date (April 1, 2025 → fully vested April 1, 2026).
- F4: Option vesting terms (if applicable) start April 1, 2026 with a typical 4‑year schedule (25% at one year, monthly thereafter).
Filing timeliness: Reported Apr 3, 2026 for transactions dated Apr 1–2, 2026 — appears timely under Form 4 reporting rules.

Context

These entries reflect derivative/RSU vesting and settlement rather than an open-market purchase signal. The small sale (26,858 shares) was a routine broker-assisted sale to cover tax withholding from the RSU vesting, not necessarily an expression of market sentiment.
For retail investors, awards and vesting disclosures show compensation events and resulting share issuance; purchases are more indicative of insider bullishness, while tax-withholding sales are common and typically routine.

Form 4

Period: 2026-04-01

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-01+775,828→ 820,407 total
Sale
Common Stock
[F2]
2026-04-02$3.48/sh−26,858$93,466→ 793,549 total
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-04-01−775,828→ 0 total
→ Common Stock (775,828 underlying)
Award
Stock Option (right to buy)
[F4]
2026-04-01+831,148→ 831,148 total
Exercise: $3.54Exp: 2036-04-01→ Common Stock (831,148 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
[F2]Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
[F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.
[F4]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

Signature

/s/ Stephen Rodin, as Attorney-in-Fact|2026-04-03

1 file